Seer, Inc., a leader in proteomics, has received significant validation for its Proteograph® Product Suite through a recent large-scale genome-wide association study (GWAS) published in Nature Genetics. Conducted under the leadership of Karsten Suhre, PhD, from Weill Cornell Medicine–Qatar, this research underscores the importance of using mass spectrometry to transform genomic signals into reliable drug targets and clinical biomarkers.
The study involved the analysis of approximately 1,600 blood samples from diverse ethnic backgrounds, featuring a discovery cohort of 1,260 and an independent replication cohort of 325. This robust framework allowed researchers to leverage Seer’s Proteograph workflow, resulting in the detection of 5,753 proteins, of which 1,980 were quantified in at least 80 percent of the participants.
Significantly, the study revealed that up to one-third of protein-gene associations identified by affinity-based assays lack replication when not validated by mass spectrometry. This finding highlights the critical need for accuracy in proteogenomics, emphasizing that traditional methods may not provide reliable results without the rigorous validation provided by mass spectrometry.
The collaboration included esteemed institutions such as Harvard Medical School and Brigham and Women’s Hospital, alongside Seer and TruDiagnostic. Their combined expertise bolstered the study’s findings, showcasing the potential of the Proteograph platform in advancing the field of genetic research.
The results of this study not only validate Seer’s technological capabilities but also set a new standard for proteomic studies. By ensuring that protein associations are rigorously verified, researchers can enhance the development of targeted therapies and improve clinical outcomes for patients.
As the field of genomics continues to evolve, the implications of this study are profound. It paves the way for more reliable biomarker discovery and reinforces the necessity of integrating advanced proteomic techniques into genetic research. Seer, Inc.’s commitment to innovation in this domain further establishes its role as a vital partner in the healthcare landscape.
